Form 8-K - Current report:
SEC Accession No. 0000950170-24-125384
Filing Date
2024-11-12
Accepted
2024-11-12 16:10:08
Documents
15
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K olma-20241112.htm   iXBRL 8-K 41566
2 EX-99.1 olma-ex99_1.htm EX-99.1 37294
3 GRAPHIC img39466132_0.jpg GRAPHIC 175497
4 GRAPHIC img39466132_1.jpg GRAPHIC 30456
5 GRAPHIC img39466132_2.jpg GRAPHIC 125368
  Complete submission text file 0000950170-24-125384.txt   652557

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT olma-20241112.xsd EX-101.SCH 23853
17 EXTRACTED XBRL INSTANCE DOCUMENT olma-20241112_htm.xml XML 4532
Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39712 | Film No.: 241448160
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)